ConductScience.org, home

Comparison · NCT02006342-a5d8eee0

Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Admitted to the ICU

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Admitted to the ICU. Trial comparisons, record NCT02006342-a5d8eee0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02006342-a5d8eee0

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.30.1450.519wilson
Risk in group 20.20.08070.416wilson
Risk difference, group 1 minus group 20.1-0.1660.349newcombe hybrid score
Risk ratio, group 1 over group 21.50.4984.52log
Odds ratio, group 1 over group 21.710.47.34log
Number needed to treat, for one more participant with the outcome on Insulin Glargine Plus Regular Insulin than on Control - Regular Insulin10from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Insulin Glargine Plus Regular Insulin
Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.~Insulin Glargine~Regular Insulin
620OG000
Group 2Control - Regular InsulinPatient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.~Regular Insulin420OG001

Outcome

Type
SECONDARY
Title
Number of Participants Admitted to the ICU
Description
The goal was to determine if the amount of patients admitted to the ICU could be reduced by providing more efficient resolution of the critical condition which is the acidosis.
Time frame
Participants followed for the duration of the Emergency Department stay, an expected average of 12 hours
Population
While one participant in the glargine group did not receive glargine, all who were enrolled were analyzed (intention to treat analysis).

Source ClinicalTrials.gov

Trial

Title
Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
NCT number
NCT02006342
Phases
NA
Conditions
Diabetic Ketoacidosis
Interventions
Insulin Glargine, Regular Insulin
Lead sponsor
The University of Texas Health Science Center, Houston
Results first posted
2017-05-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02006342-a5d8eee0